OXBRYTA
Active substance: voxelotor
TABLET, FILM COATED · VOXELOTOR 300 mg/1
United StatesActive
Marketing holder: Global Blood Therapeutics, Inc, A subsidiary of Pfizer Inc.
Verified 2026-10-09 · openFDA NDC
Analogues in other countries- Source: openFDA NDC
- Countries with the substance registered: 2
Composition
- VOXELOTOR · 300 mg/1
Analogues by country
Products with the same active substance registered in other countries.
| Country | Products |
|---|---|
| EU 1 |
|
Import and control
Control by country
- United Statesprescription only
Source: openFDA NDC · record 01a1208c-2cfa-7291-9007-f40fa474e055,01a12097-46e4-780e-ab23-f7e278899780,01a1209e-6a38-7230-bbe2-ab9f98263b96;count=3 · valid from 2026-10-09 · verified 2026-10-09
Registration
- Registration number
- 72786-102
- Registration status
- Active
- Dispensing
- Prescription only
- Route
- ORAL
Sources
- product · openFDA NDC · 72786-102 · Verified 2026-10-09 · open in source
- registration_status · openFDA NDC · 72786-102 · Verified 2026-10-09 · open in source
- ingredients.0 · openFDA NDC · 72786-102 · Verified 2026-10-09 · open in source